A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas

Cancer

Volumn 116, Issue 22, 2010, Pages 5297-5305

  Raizer, Jeffrey J ^a   Grimm, Sean ^a   Chamberlain, Marc C ^b   Nicholas, M Kelly ^c   Chandler, James P ^d   Muro, Kenji ^d   Dubner, Steven ^a   Rademaker, Alfred W ^a   Renfrow, Jaclyn ^d   Bredel, Markus ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

bevacizumab; glioblastoma; high grade glioma; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ETOPOSIDE; IRINOTECAN; LOMUSTINE; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CORRELATION ANALYSIS; DRUG EFFICACY; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECTUM HEMORRHAGE; RECURRENT CANCER; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; RECURRENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78449274656     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25462     Document Type: Article

References (35)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-2578.
3. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008; 10: 162-170.
4. Ballman KV, Buckner JC, Brown PD, et al. The relationship between 6-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007; 9: 29-38.
5. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT,. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007; 8: 610-622.
6. Gupta K, Radotra BD, Banerjee AK, Nijhawan R,. Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors. Anal Quant Cytol Histol. 2004; 26: 223-229.
7. Hong YK, Lange-Asschenfeldt B, Velasco P, et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 2004; 18: 1111-1113.
8. Nam DH, Park K, Suh YL, Kim JH,. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep. 2004; 11: 863-869.
9. Takano S, Tsuboi K, Matsumura A, Nose T,. Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts. Neuro Oncol. 2003; 5: 1-7.
10. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008; 26: 271-278.
11. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF,. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006; 66: 1258-1260.
12. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70: 779-787.
13. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13: 1253-1259.
14. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25: 4722-4729.
15. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-4740.
16. Bokstein F, Shpigel S, Blumenthal DT,. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer. 2008; 112: 2267-2273.
17. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009; 110: 173-180.
18. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009; 72: 1217-1222.
19. Chamberlain MC, Johnston S,. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009; 115: 1734-1743.
20. Chamberlain MC, Johnston S,. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol. 2009; 91: 359-367.
21. Chamberlain MC, Johnston SK,. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol. 2010; 96: 259-269.
22. Gilbert MR, Wang M, Aldape K, et al. RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM) [abstract]. J Clin Oncol. 2009; 27 (15S). Abstract 2011.
23. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG,. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-1280.
24. Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009; 11: 550-555.
25. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009; 27: 740-745.
26. Soderberg O, Gullberg M, Jarvius M, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006; 3: 995-1000.
27. Soderberg O, Leuchowius KJ, Gullberg M, et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods. 2008; 45: 227-232.
28. Fredriksson S, Gullberg M, Jarvius J, et al. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol. 2002; 20: 473-477.
29. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000; 83: 588-593.
30. Desjardins A, Reardon DA, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008; 14: 7068-7073.
31. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009; 91: 329-336.
32. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM,. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol. 2009; 27: 2905-2908.
33. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9: 157-173.
34. Kang TY, Jin T, Elinzano H, Peereboom D,. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol. 2008; 89: 113-118.
35. Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2009; 72: 1601-1606.